Patents by Inventor Ulrike Röhn

Ulrike Röhn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294505
    Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 2, 2018
    Publication date: September 5, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
  • Patent number: 11964953
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: April 23, 2024
    Assignees: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert Schmees, Ulrike Roehn, Dennis Kirchhoff, Kirstin Petersen, Mareike Grees, Nicolas Werbeck, Benjamin Bader, Rienk Offringa, Corinna Link
  • Publication number: 20230167103
    Abstract: The present invention covers aminothiazole compounds of general formula (I): in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: April 20, 2021
    Publication date: June 1, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Thi Thanh Uyen NGUYEN, Mareike GREES, Nicolas WERBECK, Ulf BOEMER, Benjamin BADER, Detlef STOECKIGT, Rienk OFFRINGA, Corinna LINK, Giambattista TESTOLIN, Katrin NOWAK-REPPEL
  • Publication number: 20230167078
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: April 20, 2021
    Publication date: June 1, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Thi Thanh Uyen NGUYEN, Mareike GREES, Nicolas WERBECK, Ulf BOEMER, Benjamin BADER, Detlef STOECKIGT, Dirk KOSEMUND, Rienk OFFRINGA, Corinna LINK, Katrin NOWAK-REPPEL
  • Publication number: 20230139936
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 4, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Mareike GREES, Nicolas WERBECK, Benjamin BADER, Rienk OFFRINGA, Corinna LINK
  • Publication number: 20230121195
    Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 12, 2022
    Publication date: April 20, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
  • Patent number: 11591311
    Abstract: The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R1, R2, R4, R5, R6, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: February 28, 2023
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Ilona Gutcher, Ulrike Röhn, Ludwig Zorn, Lars Röse, Benjamin Bader, Christina Kober, Rafael Carretero, Detlef Stöckigt, Michael Platten
  • Patent number: 11524944
    Abstract: The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 13, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien Lefranc, Norbert Schmees, Ulrike Röhn, Ludwig Zorn, Judith Günther, Ilona Gutcher, Lars Röse, Benjamin Bader, Detlef Stöckigt, Michael Platten
  • Patent number: 11459312
    Abstract: Disclosed are compounds of general formula (I): wherein R1, R2, A, X, Y and Z are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: October 4, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ludwig Zorn, Ulrike Röhn, Ilona Gutcher, Lars Röse, Benjamin Bader, Christina Kober, Rafael Carretero, Detlef Stöckigt, Michael Platten
  • Patent number: 11304946
    Abstract: The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: April 19, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien Lefranc, Norbert Schmees, Ulrike Röhn, Ludwig Zorn, Judith Günther, Ilona Gutcher, Lars Röse, Benjamin Bader, Detlef Stöckigt, Michael Platten
  • Patent number: 11161825
    Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: November 2, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Weiske, Carlo Stresemann, Stefan Nikolaus Gradl, Ulrike Röhn, Clara Christ, Holger Steuber, Manfred Husemann, Norbert Schmees, Kai Thede, Stephan Siegel, Antonius Ter Laak
  • Patent number: 11040035
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 22, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert Schmees, Ilona Gutcher, Horst Irlbacher, Benjamin Bader, Na Zhao, Michael Platten, Ulrike Röhn, Ludwig Zorn, Lars Röse, Detlef Stöckigt
  • Publication number: 20200299269
    Abstract: The present invention covers sulphur substituted 3-oxo-2,3-dihydropyridazine-4 carboxamide compounds of general formula (I): (I) in which R1, R2, A, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 24, 2020
    Inventors: Ludwig ZORN, Ulrike RÖHN, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200289509
    Abstract: The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2017
    Publication date: September 17, 2020
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200283395
    Abstract: The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 10, 2020
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200283402
    Abstract: The present invention covers 3-oxo-6-heteromyl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R1, R2, R4, R5, R6, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 10, 2020
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200237757
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 23, 2017
    Publication date: July 30, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert SCHMEES, Ilona GUTCHER, Horst IRLBACHER, Benjamin BADER, Na ZHAO, Michael PLATTEN, Ulrike ROEHN, Ludwig ZORN, Lars ROESE, Detlef STOECKIGT
  • Publication number: 20200199083
    Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 9, 2018
    Publication date: June 25, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WEISKE, Carlo STRESEMANN, Stefan Nikolaus GRADL, Ulrike RÖHN, Clara CHRIST, Holger STEUBER, Manfred HUSEMANN, Norbert SCHMEES, Kai THEDE, Stephan SIEGEL, Antonius TER LAAK
  • Patent number: 9655887
    Abstract: The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: May 23, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Bernhard Lindenthal, Nico Bräuer, Peter Serno, Andrea Rotgeri, Ulrike Fuhrmann, Bernd Buchmann, Anne Mengel, Ulrike Röhn, Antonius Ter Laak
  • Publication number: 20160280699
    Abstract: The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.
    Type: Application
    Filed: September 24, 2014
    Publication date: September 29, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrike RÖHN, Manuel ELLERMANN, Julia STRAßBURGER, Astrid WENDT, Susanne RÖHRIG, Robert Alan WEBSTER, Martina Victoria SCHMIDT, Adrian TERSTEEGEN, Kristin BEYER, Martina SCHÄFER, Anja BUCHMÜLLER, Christoph GERDES, Michael SPERZEL, Steffen SANDMANN, Stefan HEITMEIER, Alexander HILLISCH, Jens ACKERSTAFF, Carsten TERJUNG